CME: Offering mifepristone as an abortion option

Article

While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.

Recent Videos
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
Integrase inhibitors not linked to neonatal weight | Image Credit: linkedin.com
Dr. Thomas outlines the future of the Safe Baby Safe Moms program | Image Credit: medstarhealth.org.
How the Safe Baby Safe Moms program transforms maternal and child health | Image Credit: medstarhealth.org.
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
The importance of nipocalimab’s FTD against FNAIT | Image Credit:  linkedin.com
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Related Content
© 2025 MJH Life Sciences

All rights reserved.